Induction immunochemotherapy followed by definitive radiotherapy in patients with limited-stage small cell lung cancer: a multicenter study [0.03%]
小细胞肺癌局限性期患者诱导免疫化疗后进行根治性放疗的多中心研究
Junxu Wen,Qian Wang,Xinrui Yu et al.
Junxu Wen et al.
Lenvatinib triggers an EGR1-ZNF768-SLC7A11 adaptive response to limit ferroptosis-mediated therapeutic efficacy in hepatocellular carcinoma [0.03%]
仑伐替尼通过触发EGR1-ZNF768-SLC7A11适应性反应限制铁死亡介导的治疗效果以促进肝细胞癌耐药形成
Jialei Hua,Shuya Zhao,Changsen Bai et al.
Jialei Hua et al.
Objective: Adaptive therapeutic tolerance frequently limits first-line lenvatinib efficacy in hepatocellular carcinoma (HCC). This study explored the C2H2-type zinc finger (ZNF) protein family (the largest class of transc...
Probiotics in colorectal cancer: mechanisms, biomarkers, and adjunct strategies [0.03%]
益生菌在结直肠癌中的作用：机制、生物标志物和辅助策略
Zihe Xu,Lan Mu,Hao Su et al.
Zihe Xu et al.
Colorectal cancer (CRC) is among the most common malignant tumors and remains a leading cause of cancer-related mortality worldwide. The gut microbiota and metabolites, which are modulated by host genetics and environmental exposures, have ...
Bifidobacterium animalis suppresses melanoma progression and activates anti-tumor immunity by inhibiting YAP1 expression in CD8+ T cells [0.03%]
动物双歧杆菌通过抑制CD8+T细胞中YAP1表达来抑制黑色素瘤的进展并激活抗肿瘤免疫反应
Chengyi Li,Xuehua Zhang,Yichen Yang et al.
Chengyi Li et al.
Objective: The probiotic, Bifidobacterium animalis, (B. animalis) is known to provide health benefits in humans. This study investigated the role of B. animalis in suppressing malignant melanoma progression and modulating...
Gut microbiota and pancreatic cancer: tumorigenesis, progression, and clinical applications [0.03%]
肠道菌群与胰腺癌：肿瘤发生、进展及临床应用
Chuxiong Cheng,Jingsong Wang,Jin Xie et al.
Chuxiong Cheng et al.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies of the digestive system, with a 5-year survival rate of only 13%, which is largely due to late-stage diagnosis and limited therapeutic options. Emerging evid...
Tumor microenvironment-driven natural killer cell diversity: mechanisms and therapeutic opportunities [0.03%]
肿瘤微环境驱动的天然杀伤细胞多样性：机制和治疗机会
Yue Duan,Mingzhen Zhou,Xingxian Guo et al.
Yue Duan et al.
Natural killer (NK) cells are key effector cells involved in tumor immune surveillance, yet their function within the tumor microenvironment (TME) exhibits considerable complexity and plasticity that cannot be adequately explained by the cl...
Dietary nitrate drives gastritis by modulating gastric microbiota and metabolites [0.03%]
膳食硝酸盐通过调控胃部微生物组和代谢物驱动胃炎产生
Lanping Jiang,Tianhui Li,Jiayu Wu et al.
Lanping Jiang et al.
Objective: Dietary nitrate has been increasingly recognized as a potential carcinogen associated with gastritis. In this study the mechanistic role of a high-nitrate diet (NaD) in driving gastritis was elucidated with a f...
Evolution in single-cell proteomics drives new frontiers in cancer biology and precision medicine [0.03%]
单细胞蛋白质组学的进化推动了癌症生物学和精准医学的新进展
Yi Liu,Yingdong Du,Ran Su et al.
Yi Liu et al.
The inherent heterogeneity of cancer leads to varied responses to treatment and underscores the need for the development of precision medicine. Single-cell proteomics is crucial for deciphering intra- and inter-tumor heterogeneity. Mass cyt...
Design principles of nanomaterials for cancer immunotherapy: a mechanistic framework across the cancer immunity cycle [0.03%]
癌症免疫周期的纳米材料设计原则：机制框架
Yating Bai,Zhihao Lan,Nana Feng et al.
Yating Bai et al.
Cancer immunotherapy has revolutionized oncology by harnessing the immune system to eliminate malignant cells, yet its efficacy remains constrained by insufficient antigen presentation, limited T cell infiltration, and the immunosuppressive...
Opportunities and challenges of immunotherapy for patients with resectable and potentially resectable stage III non-small cell lung cancer [0.03%]
可切除和潜在可切除的III期非小细胞肺癌患者的免疫治疗机遇与挑战
Yuzhen Cui,Jingdong Xu,Junxu Wen et al.
Yuzhen Cui et al.
The integration of immune checkpoint inhibitors has transformed the therapeutic landscape for patients with resectable and potentially resectable stage III non-small cell lung cancer, providing unprecedented opportunities for curative treat...